Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Shogo Nakamoto"'
Autor:
Shogo Nakamoto, Tadahiko Shien, Takayuki Iwamoto, Shinichiro Kubo, Mari Yamamoto, Tetsumasa Yamashita, Chihiro Kuwahara, Masahiko Ikeda
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are the standard agents for treating patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer (ER + HER2 − ABC). However, mar
Externí odkaz:
https://doaj.org/article/095db8af48464a8a8b01067338c59fbf
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Eribulin methylate (eribulin) improved the overall survival (OS) of eribulin-treated patients with HER2-negative advanced breast cancer (ABC) in prospective and retrospective studies. However, the effect of eribulin on OS as first
Externí odkaz:
https://doaj.org/article/c0dea0975b144769825cbd927e481ae6
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Post-progression survival affects overall survival (OS) in patients with HER2-negative advanced breast cancer (HER2-ABC); thus, the optimal choice of first-line chemotherapy (1LCT) remains controversial. We investigated patients with HER2-AB
Externí odkaz:
https://doaj.org/article/86285e9b6b9e4519a0e2732749a6ffd2
Autor:
Shogo Nakamoto, Masahiko Ikeda, Shinichiro Kubo, Mari Yamamoto, Tetsumasa Yamashita, Akifumi Notsu
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness remain undefined. We investigated the usefulness of systemic
Externí odkaz:
https://doaj.org/article/14dd1034bcb343bd9620773f8414331d
Autor:
Taiyo L. Harada, Kazuaki Nakashima, Takayoshi Uematsu, Takashi Sugino, Seiichirou Nishimura, Kaoru Takahashi, Yukiko Tadokoro, Tomomi Hayashi, Junichiro Watanabe, Shogo Nakamoto
Publikováno v:
European Journal of Radiology Open, Vol 6, Iss , Pp 302-306 (2019)
A 63-year-old woman was referred to our hospital for breast cancer treatment. She had a large HER2-positive breast tumor on her left breast, and received neoadjuvant chemotherapy. After treatment, a shrunk spiculated mass with calcification-like high
Externí odkaz:
https://doaj.org/article/7b58de4ba7064c788fb9c55a1c0c0bf5
Autor:
Shogo Nakamoto, Masahiko Ikeda, Chihiro Kuwahara, Shinichiro Kubo, Tetsumasa Yamashita, Mari Yamamoto
Publikováno v:
Cancer Diagn Progn
Background/Aim: We investigated the efficacy and safety of sorafenib in Japanese patients and the prognostic value of systemic immunity markers for predicting clinical outcomes after sorafenib therapy in patients with radioiodine refractory different
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::582aabb5646522ec3a1c55c5a42d442e
https://doi.org/10.21873/cdp.10066
https://doi.org/10.21873/cdp.10066
Autor:
Nakamasa Hayashi, Yoko Nakasu, Shogo Nakamoto, Shoichi Deguchi, Junichiro Watanabe, Hideyuki Harada, Koichi Mitsuya
Publikováno v:
Breast Cancer Research and Treatment. 189:225-236
While leptomeningeal metastasis (LM) from estrogen receptor-positive, HER2-negative advanced breast cancer (ER + HER2-ABC) has a poor prognosis, the details of ER + HER2-LM are unclear. We therefore retrospectively investigated patients with LM from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d142cd5e5772ff31f53036d9f6b1a10
https://doi.org/10.1007/s10549-021-06246-z
https://doi.org/10.1007/s10549-021-06246-z
Autor:
Taiyo L Harada, Shogo Nakamoto, Kaoru Takahashi, Takahiro Ito, Tomomi Hayashi, Yukiko Tadokoro, Kazuaki Nakashima, Takayoshi Uematsu, Junichiro Watanabe, Takashi Sugino, Seiichirou Nishimura
Publikováno v:
European Radiology. 30:3363-3370
Given that a pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) is an important prognostic factor, evaluating pretreatment imaging findings is important. Outcomes for triple negative breast cancer (TNBC) vary with the histologi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6be06ca6262f1373f625b9a5286cdb07
https://doi.org/10.1007/s00330-020-06662-7
https://doi.org/10.1007/s00330-020-06662-7
Autor:
Junichiro Watanabe, Takashi Sugino, Koji Muramatsu, Satoshi Morita, Yu Hidaka, Shogo Nakamoto, Mitsuya Ito, Shoichiro Ohtani, Masahiko Ikeda
Publikováno v:
Cancer Research. 83:P5-02
Background: In IMpassion 130 trial, programmed death-ligand 1 (PD-L1) expression was seen in about 40% of participated patients with triple negative advanced breast cancer (TN-ABC) [Schmid, 2018, N Engl J Med], however, actual situation of PD-L1 expr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a2de8d14b71b56b8e79c814b22fd6ad
https://doi.org/10.1158/1538-7445.sabcs22-p5-02-48
https://doi.org/10.1158/1538-7445.sabcs22-p5-02-48
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Post-progression survival affects overall survival (OS) in patients with HER2-negative advanced breast cancer (HER2-ABC); thus, the optimal choice of first-line chemotherapy (1LCT) remains controversial. We investigated patients with HER2-ABC focusin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7faf887af3fe154cf8d074f7ca591408
http://europepmc.org/articles/PMC8563944
http://europepmc.org/articles/PMC8563944